IP Library › Granted Patent US 12,171,812
Granted Patent B2
US 12,171,812 · App. 18/172,787 · Granted Dec 24, 2024

Anti-inflammatory peptides and composition comprising the same

Inventors: Sang Jae Kim (Seoul, KR); Kyung Hee Kim (Seongnam-si, KR); Kyu-Yong Lee (Seongnam-si, KR); Seong-Ho Koh (Seongnam-si, KR); Hyun-Hee Park (Seongnam-si, KR); Sung Jin Huh (Seongnam-si, KR); Woo Jin Lee (Seongnam-si, KR); Bum Joon Kim (Seongnam-si, KR)
Assignee: GemVax & KAEL Co., Ltd.
A61K38/45A23L33/18A61K8/64A61Q19/00C07K7/08C07K14/4703C12N9/0069C12N9/0083C12Y113/11C12Y114/99001C12Y207/07049A23V2002/00A61K38/00Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,171,812
App. No.
18/172,787
Granted
Dec 24, 2024
Kind
B2
Abstract

A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. An inflammatory composition comprising the above mentioned peptides is also described. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.

Claims (4)

1. An anti-inflammatory composition comprising an isolated peptide consisting of the amino acid sequence of SEQ ID NO:116 as an active ingredient, wherein the isolated peptide has anti-inflammatory activity.

2. The anti-inflammatory composition according to claim 1 for treatment of inflammatory diseases, wherein the inflammatory disease is central or peripheral nervous system related disease.

3. The anti-inflammatory composition according to claim 1 , which is a pharmaceutical composition for treatment of inflammatory diseases, wherein the inflammatory disease is central or peripheral nervous system related disease.

4. The anti-inflammatory composition according to claim 3 , wherein the central or peripheral nervous system related disease is selected from the group consisting of Alzheimer's disease, meningitis, encephalitis, multiple sclerosis, cerebral infarction, cerebral embolism, Guillain-Barre syndrome, neuritis, neuralgia, spinal cord injury, paralysis, and uveitis.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 068509/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2024
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 068583/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2024
From: KIM, KYUNG HEE; LEE, KYU-YONG; KOH, SEONG-HO; PARK, HYUN-HEE; HUH, SUNG JIN; LEE, WOO JIN; KIM, BUM JOON
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 068617/0825 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
Priority Claims (5)
KR 10-2012-0050529 · May 11, 2012 · national
KR 10-2012-0050533 · May 11, 2012 · national
KR 10-2012-0071989 · Jul 2, 2012 · national
KR 10-2012-0104144 · Sep 19, 2012 · national
KR 10-2012-0104207 · Sep 19, 2012 · national
Continuity (5)
Division 17112935 · Dec 4, 2020
Division 16230732 · Dec 21, 2018
Division 15354139 · Nov 17, 2016
Division 14400321
Related Publication 20230293644A1 · Sep 21, 2023